About Us

Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. Rapid turnaround times, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. The io® platform offers a sample-­to-­answer time of 30 minutes, or less, making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices anywhere.

Executive Leadership

Jeff has served as CEO of multiple life sciences companies in emerging healthcare markets with both public and private venture-backed companies. Prior to Atlas Genetics, Jeff served as President, Chief Executive Officer and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Mr. Luber’s leadership, the Company grew testing volumes by double digits, established transformative industry partnerships, and led the Company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017. Prior to Good Start, Mr. Luber co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism. From 2002 to 2009 Mr. Luber held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Luber has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.
Marc is a proven financial and operations executive who brings extensive expertise in leading financial, operational and business strategy aspects and capital formation for both large and small, public and private healthcare and technology organizations. Prior to joining Atlas Genetics, Marc was the COO & CFO of Good Start Genetics where he raised multiple successful rounds of capital, helped lead the impressive turnaround of the company to record business growth and was instrumental in its ultimate sale to publicly traded Invitae. Prior to Good Start Marc was CFO of T2 Biosystems, where he led the company's preparation for and completion of an IPO and raised nearly $100M ($70M equity + $30M in debt); he built the finance team and implemented the necessary infrastructure and processes required of a public company, and he helped drive the commercialization of the company's first FDA approved IVD product. Previously, Marc was CFO of Crashlytics where he oversaw the company's acquisition by Twitter (the largest acquisition completed by Twitter at that time). Before Crashlytics, Marc was CFO of Ivenix where he led all finance, admin and operations functions, including raising over $8M in capital. Before that, Marc served as CFO of CHiL Semiconductor, where he oversaw growth from pre-revenue to a $20M run-rate, raised $30M in venture financing, and the ultimate acquisition of the company. Earlier in his career Marc held a number of other corporate finance positions ranging from Fortune 50 companies to high-growth startups.
Ben joined Atlas Genetics as Technical Director in 2008. With a background in mechanical engineering he has spent his career working in innovation and new product development. His experience includes working in products from drug delivery devices to in vitro diagnostics. Ben spent four years in the US managing an engineering team in Boston as part of a new venture.

Board of Directors

John has a background in molecular biology and significant experience in healthcare and diagnostics businesses. He co-founded Molecular Sensing plc where he was Commercial Director and then Technical Director. Following the successful development of their DNA analysis system, he joined the US-based diagnostics company Osmetech plc when they acquired Molecular Sensing in 2004. John led the formation of Atlas Genetics in 2005 and was founding Chief Executive before becoming Chairman in 2017.
Lapidus founded EXACT Sciences and served as its CEO and Chairman until 2006. Since commercial introduction of the company’s Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry. Prior to EXACT Sciences, Lapidus was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2 billion. He is the principal inventor of Cytyc’s ThinPrep Pap test, which revolutionized screening for cervical cancer and now accounts for approximately 80% of the world market for cervical cancer screening. Lapidus was also the founder and CEO of SynapDx and Helicos Biosciences. Currently, Lapidus serves as a director to a number of public and private medical device and diagnostics companies, and he was an instructor at MIT from 2001 to 2017. Lapidus is a seasoned innovator holding 36 U.S. patents. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2013 for his work on the early detection of cancer. Lapidus graduated from Cooper Union in New York City with a BS degree in electrical engineering.
The majority of Neil’s career has involved managing technology businesses, with the past 17 years focused on medical diagnostics within young entrepreneurial companies. He has been the founding CEO of 3 diagnostic businesses: Oxford Biosensors, Vivacta and Spectromics and currently participates on the boards of 4 diagnostic companies (Genomic Vision, Atlas Genetics, Radisens and Spectromics). For the past 7 years he has also carried out due diligence for a number of European and US VC’s on diagnostic related investments. He is also a Strategic Advisory Team member for EPSRC.

He has worked on a full spectrum of analytical technologies including immunochemistry, electrochemistry, nucleic acid, cell counting, single cell analysis, sequencing and genomic physical mapping for structural variants. An engineer by trade that has spent most of his career in material science and biology related sectors.

His earlier career was spent in both US and European large corporates involving polymers and semi-finished products used in drug delivery, woundcare, medical devices and electronics.

Jonathan was Group Finance Director of Consort Medical plc from September 2006 to December 2007 until he took up the position of Chief Executive Officer in December 2007. Prior to joining Consort Medical plc, Jonathan was global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the life sciences industry. Jonathan joined Tissue Regenix Group plc as a non-executive director in January 2016 and is an investor director of Atlas Genetics Limited.

Jonathan is a member of the Institute of Chartered Accountants in England and Wales.

Maxim Gorbachev has served as a member of Atlas genetics board of directors since January 2015. Mr. Gorbachev serves on our audit committee. Mr. Gorbachev is a managing partner at RMI Partners, a Russian-based life sciences venture capital firm, which he joined in March 2013.
He is also a member of the Board of Directors of Neothetics, Inc. (NASDAQ:NEOT) and Celtaxsys, Inc
Mr.Gorbachev has more then 20 years of professional experience. Before joining RMI Partners, he worked in various positions at the global pharmaceutical company UCB Pharma. His professional track record includes work experience at Russian production companies, investment and consulting firms.

Mr. Gorbachev earned a M.S. in applied mathematics from Lomonosov Moscow State University, a M.S. in Financial Management from The Finance University under The Government of Russian Federation and an M.B.A. from Vlerick Business School.

He is a member of the Russian Association of Independent Directors.

Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner of the firm.
Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland.
He serves or has served on the boards of 4-Antibody (CH, now NASDAQ: AGEN), Affectis (D), Atlas Genetics (UK), Atugen (D, now LSE:SLN Silence Therapeutics), Bioxell (I, now SIX: Cosmo Pharmaceuticals), Cardior (D), Cellerix (E, now NYSE Euronext: Tigenix), IDEA (D), Morphochem (D, now: Biovertis), Idenix (USA, then NASDAQ: IDIX, now Merck), Luxendo (D, now Bruker Corp), Nouscom (CH), Okairos (CH, now: GSK), Omrix Biopharmaceuticals (NYSE: OMRI, then J&J), Scion Pharmaceuticals (USA), t.Breeders (NASDAQ: Viacell, then NYSE:PKI) and U3 Pharma (D, now: Daiichi-Sankyo). In addition, he serves pro bono on the boards of various tech transfer organizations such as Ascenion, AWS, or the Life Science Incubator.
Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature.

Dr. Martin Münchbach is a Managing Partner and Investment Advisor Private Equity at BB Biotech Ventures and Bellevue Asset Management since 2004. He has been an active venture capitalist since the late 90’s investing in life science companies across all stages and types. Prior to joining Bellevue Group, he was Investment Manager at BioMed, HBM and NMT. Martin’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan and Glycart. Martin holds a PhD in Protein Chemistry, an MSc in Biochemistry and a Master in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zürich.

Chris Price graduated from the University of London with a degree in Chemistry and Physiology, obtaining his PhD from the University of Birmingham. He trained as a clinical biochemist and has experience in the National Health Service (NHS) as well as in the academic and commercial sectors. His NHS work included laboratory positions in major hospitals in Coventry, Birmingham, Southampton, Cambridge and London. He was Professor of Clinical Biochemistry at the St Bartholomews and the Royal London School of Medicine and Dentistry, as well as being Director of Pathology at the associated teaching hospital for a number of years.
One of Chris’s interests has been the adaptation of the principles of evidence-based medicine to diagnostics (laboratory medicine) along with developing the concept of a value proposition for diagnostics to promote better, more informed adoption of diagnostic services as part of an outcomes, and value-based, approach to health care delivery. Critically this focuses on the value to all stakeholders in healthcare provision, rather than considering tests as a commodity. He spent four years with the Diagnostics Division of Bayer Healthcare as Vice President of Outcome Research.
Chris’s research record has been one based on collaboration with clinicians in the primary care sectors, with scientists from other disciplines and with the commercial sector. One of his research groups, working with a Porton Down biotechnology group developed the first enzymatic assays for paracetamol (acetaminophen) and phenylalanine to produce world beating methods. Another group, working with the DuPont company developed a number of rapid light scattering assays, including the first rapid, automated, assay for cystatin C. Several of the assays were commercialised and Chris holds several patients in these areas.
Chris is a recognised leader in the field of point-of-care testing (POCT) with a large body of published work, including five books, putting POCT into context across the breadth of the healthcare economy. The work includes development and technical evaluations of new technology, as well as the clinical application of new technologies in the clinical setting. All of this experience has ben brought together in recent years as a Visiting Professor and Honorary Senior Fellow at the University of Oxford, including an NIHR funded project to encourage closer collaboration between the NHS, academia and the commercial sector to encourage more successful adoption of new diagnostic technologies in healthcare.
Chris has been a Non-Executive Director at Atlas Genetics for the last ten years.

Ms. Wang has served on the board of directors of Atlas Genetics since January 2017.  Been the first generation of pioneer in establishing private biotechnology companies in China, Ms. Wang founded Guangzhou Wondfo Biotech Co., Ltd, in 1992, and served as the CEO until June 2016.  After leading the company to IPO in 2015, Ms. Wang has been appointed as Chairman of Board since July 2016.  Since 2009, Ms. Wang has been the President of Wondfo USA, where she oversees global strategic planning.  She has extensive experience in IVD technology and healthcare business.  Ms. Wang received a B.S. from Hunan Medical University and M. S. from State Key Laboratory of Enzyme Engineering of Jilin University.  She worked as a visiting scholar in Harvard Medical School in 2000.


Atlas Genetics has raised approximately £63m to date from a strong investor base. The last financing raised was £28m ($35m) Series D (2016) raised from a syndicate including all Series C investors, Novartis Venture Funds, Johnson & Johnson Development Corporation, LSP (Life Science Partners), BB Biotech Ventures, Consort Medical plc, Technology Venture Partners, RMI Partners and private investors, plus Chinese biotechnology company, Wondfo Biotech.


Public Grants

Atlas Genetics has been awarded grant funding from the South West Regional Development Agency (SWRDA), The Wellcome Trust, the United States Institutes of Health, and a £1.6m project from The Technology Strategy Board, in partnership with Public Health England and £2m from Innovate UK as part of the Small Business Research Initiative.


Atlas Genetics is engaged in a number of collaborative projects with major diagnostic and pharmaceutical companies, and various public bodies. We aim to utilise Atlas Genetics’ technology in specific applications outside of the Company’s core product area of STIs to expand the utility of the io® platform.